Collectively, these clinical data, coupled with our previous findings that reduced FBXO7 induces CIN that promotes cellular transformation,11 are consistent with FBXO7 copy number losses being a pathogenic contributor in CRC and identify FBXO7 as an ideal target to exploit using an SL paradigm. This evidence concerns the gene FBXO7 and colorectal carcinoma.